Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Jan;33(1):3–9. doi: 10.1111/j.1365-2125.1992.tb03993.x

The human platelet fibrinogen receptor: clinical and therapeutic significance.

M Cahill 1, R Mistry 1, D B Barnett 1
PMCID: PMC1381192  PMID: 1540487

Full text

PDF
3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett J. S., Hoxie J. A., Leitman S. F., Vilaire G., Cines D. B. Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. Proc Natl Acad Sci U S A. 1983 May;80(9):2417–2421. doi: 10.1073/pnas.80.9.2417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bray P. F., Rosa J. P., Lingappa V. R., Kan Y. W., McEver R. P., Shuman M. A. Biogenesis of the platelet receptor for fibrinogen: evidence for separate precursors for glycoproteins IIb and IIIa. Proc Natl Acad Sci U S A. 1986 Mar;83(5):1480–1484. doi: 10.1073/pnas.83.5.1480. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cadroy Y., Houghten R. A., Hanson S. R. RGDV peptide selectively inhibits platelet-dependent thrombus formation in vivo. Studies using a baboon model. J Clin Invest. 1989 Sep;84(3):939–944. doi: 10.1172/JCI114256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Clezardin P., McGregor J. L., Dechavanne M., Clemetson K. J. Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. Br J Haematol. 1985 Jun;60(2):331–344. doi: 10.1111/j.1365-2141.1985.tb07419.x. [DOI] [PubMed] [Google Scholar]
  5. Coller B. S., Folts J. D., Smith S. R., Scudder L. E., Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor. Correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors. Circulation. 1989 Dec;80(6):1766–1774. doi: 10.1161/01.cir.80.6.1766. [DOI] [PubMed] [Google Scholar]
  6. Cook N. S., Ubben D. Fibrinogen as a major risk factor in cardiovascular disease. Trends Pharmacol Sci. 1990 Nov;11(11):444–451. doi: 10.1016/0165-6147(90)90125-r. [DOI] [PubMed] [Google Scholar]
  7. Defreyn G., Bernat A., Delebassee D., Maffrand J. P. Pharmacology of ticlopidine: a review. Semin Thromb Hemost. 1989 Apr;15(2):159–166. doi: 10.1055/s-2007-1002699. [DOI] [PubMed] [Google Scholar]
  8. Dennis M. S., Henzel W. J., Pitti R. M., Lipari M. T., Napier M. A., Deisher T. A., Bunting S., Lazarus R. A. Platelet glycoprotein IIb-IIIa protein antagonists from snake venoms: evidence for a family of platelet-aggregation inhibitors. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2471–2475. doi: 10.1073/pnas.87.7.2471. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Derian C. K., Friedman P. A. Effect of ticlopidine ex vivo on platelet intracellular calcium mobilization. Thromb Res. 1988 Apr 1;50(1):65–76. doi: 10.1016/0049-3848(88)90175-2. [DOI] [PubMed] [Google Scholar]
  10. Di Minno G., Capitanio A. M., Thiagarajan P., Martinez J., Murphy S. Exposure of fibrinogen receptors on fresh and stored platelets by ADP and epinephrine as single agents and as a pair. Blood. 1983 Jun;61(6):1054–1059. [PubMed] [Google Scholar]
  11. Di Minno G., Cerbone A. M., Mattioli P. L., Turco S., Iovine C., Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest. 1985 Feb;75(2):328–338. doi: 10.1172/JCI111705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Dunn F. W., Soria J., Soria C., Thomaidis A., Lee H., Caen J. P. In vivo effect of ticlopidine on fibrinogen-platelet cofactor activity and binding of fibrinogen to platelets. Agents Actions Suppl. 1984;15:97–104. doi: 10.1007/BF01966985. [DOI] [PubMed] [Google Scholar]
  13. Fitzgerald D. J., Wright F., FitzGerald G. A. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A2 modulate the response to tissue-type plasminogen activator in vivo. Circ Res. 1989 Jul;65(1):83–94. doi: 10.1161/01.res.65.1.83. [DOI] [PubMed] [Google Scholar]
  14. Féliste R., Delebassée D., Simon M. F., Chap H., Defreyn G., Vallée E., Douste-Blazy L., Maffrand J. P. Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effects of released ADP. Thromb Res. 1987 Nov 15;48(4):403–415. doi: 10.1016/0049-3848(87)90398-7. [DOI] [PubMed] [Google Scholar]
  15. Gachet C., Cazenave J. P., Ohlmann P., Bouloux C., Defreyn G., Driot F., Maffrand J. P. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1. Biochem Pharmacol. 1990 Dec 15;40(12):2683–2687. doi: 10.1016/0006-2952(90)90587-b. [DOI] [PubMed] [Google Scholar]
  16. Gent M., Blakely J. A., Easton J. D., Ellis D. J., Hachinski V. C., Harbison J. W., Panak E., Roberts R. S., Sicurella J., Turpie A. G. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989 Jun 3;1(8649):1215–1220. doi: 10.1016/s0140-6736(89)92327-1. [DOI] [PubMed] [Google Scholar]
  17. Gold H. K., Gimple L. W., Yasuda T., Leinbach R. C., Werner W., Holt R., Jordan R., Berger H., Collen D., Coller B. S. Pharmacodynamic study of F(ab')2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest. 1990 Aug;86(2):651–659. doi: 10.1172/JCI114757. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hardisty R. M., Powling M. J., Nokes T. J. The action of ticlopidine on human platelets. Studies on aggregation, secretion, calcium mobilization and membrane glycoproteins. Thromb Haemost. 1990 Aug 13;64(1):150–155. [PubMed] [Google Scholar]
  19. Haskel E. J., Adams S. P., Feigen L. P., Saffitz J. E., Gorczynski R. J., Sobel B. E., Abendschein D. R. Prevention of reoccluding platelet-rich thrombi in canine femoral arteries with a novel peptide antagonist of platelet glycoprotein IIb/IIIa receptors. Circulation. 1989 Dec;80(6):1775–1782. doi: 10.1161/01.cir.80.6.1775. [DOI] [PubMed] [Google Scholar]
  20. Hass W. K., Easton J. D., Adams H. P., Jr, Pryse-Phillips W., Molony B. A., Anderson S., Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989 Aug 24;321(8):501–507. doi: 10.1056/NEJM198908243210804. [DOI] [PubMed] [Google Scholar]
  21. Janzon L., Bergqvist D., Boberg J., Boberg M., Eriksson I., Lindgärde F., Persson G., Almgren B., Fagher B., Kjellström T. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med. 1990 May;227(5):301–308. doi: 10.1111/j.1365-2796.1990.tb00164.x. [DOI] [PubMed] [Google Scholar]
  22. Kroll M. H., Schafer A. I. Biochemical mechanisms of platelet activation. Blood. 1989 Sep;74(4):1181–1195. [PubMed] [Google Scholar]
  23. Landolfi R., De Cristofaro R., Castagnola M., De Candia E., D'Onofrio G., Leone G., Bizzi B. Increased platelet-fibrinogen affinity in patients with myeloproliferative disorders. Blood. 1988 Apr;71(4):978–982. [PubMed] [Google Scholar]
  24. Marguerie G. A., Plow E. F., Edgington T. S. Human platelets possess an inducible and saturable receptor specific for fibrinogen. J Biol Chem. 1979 Jun 25;254(12):5357–5363. [PubMed] [Google Scholar]
  25. Mazzucato M., De Marco L., De Angelis V., De Roia D., Bizzaro N., Casonato A. Platelet membrane abnormalities in myeloproliferative disorders: decrease in glycoproteins Ib and IIb/IIIa complex is associated with deficient receptor function. Br J Haematol. 1989 Nov;73(3):369–374. doi: 10.1111/j.1365-2141.1989.tb07755.x. [DOI] [PubMed] [Google Scholar]
  26. McEver R. P., Bennett E. M., Martin M. N. Identification of two structurally and functionally distinct sites on human platelet membrane glycoprotein IIb-IIIa using monoclonal antibodies. J Biol Chem. 1983 Apr 25;258(8):5269–5275. [PubMed] [Google Scholar]
  27. Mistry R., Cahill M., Chapman C., Wood J. K., Barnett D. B. 125I-fibrinogen binding to platelets in myeloproliferative disease. Thromb Haemost. 1991 Sep 2;66(3):329–333. [PubMed] [Google Scholar]
  28. Oates J. A., FitzGerald G. A., Branch R. A., Jackson E. K., Knapp H. R., Roberts L. J., 2nd Clinical implications of prostaglandin and thromboxane A2 formation (1). N Engl J Med. 1988 Sep 15;319(11):689–698. doi: 10.1056/NEJM198809153191106. [DOI] [PubMed] [Google Scholar]
  29. Oates J. A., FitzGerald G. A., Branch R. A., Jackson E. K., Knapp H. R., Roberts L. J., 2nd Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med. 1988 Sep 22;319(12):761–767. doi: 10.1056/NEJM198809223191206. [DOI] [PubMed] [Google Scholar]
  30. Palareti G., Poggi M., Torricelli P., Balestra V., Coccheri S. Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease. Thromb Res. 1988 Dec 15;52(6):621–629. doi: 10.1016/0049-3848(88)90134-x. [DOI] [PubMed] [Google Scholar]
  31. Peerschke E. I., Zucker M. B., Grant R. A., Egan J. J., Johnson M. M. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood. 1980 May;55(5):841–847. [PubMed] [Google Scholar]
  32. Phillips D. R., Baughan A. K. Fibrinogen binding to human platelet plasma membranes. Identification of two steps requiring divalent cations. J Biol Chem. 1983 Sep 10;258(17):10240–10246. [PubMed] [Google Scholar]
  33. Phillips D. R., Charo I. F., Parise L. V., Fitzgerald L. A. The platelet membrane glycoprotein IIb-IIIa complex. Blood. 1988 Apr;71(4):831–843. [PubMed] [Google Scholar]
  34. Plow E. F., Ginsberg M. H. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. Prog Hemost Thromb. 1989;9:117–156. [PubMed] [Google Scholar]
  35. Plow E. F., Marguerie G., Ginsberg M. Fibrinogen, fibrinogen receptors, and the peptides that inhibit these interactions. Biochem Pharmacol. 1987 Dec 1;36(23):4035–4040. doi: 10.1016/0006-2952(87)90558-2. [DOI] [PubMed] [Google Scholar]
  36. Plow E. F., Marguerie G. Inhibition of fibrinogen binding to human platelets by the tetrapeptide glycyl-L-prolyl-L-arginyl-L-proline. Proc Natl Acad Sci U S A. 1982 Jun;79(12):3711–3715. doi: 10.1073/pnas.79.12.3711. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ruggeri Z. M., Houghten R. A., Russell S. R., Zimmerman T. S. Inhibition of platelet function with synthetic peptides designed to be high-affinity antagonists of fibrinogen binding to platelets. Proc Natl Acad Sci U S A. 1986 Aug;83(15):5708–5712. doi: 10.1073/pnas.83.15.5708. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Shattil S. J., Brass L. F. Induction of the fibrinogen receptor on human platelets by intracellular mediators. J Biol Chem. 1987 Jan 25;262(3):992–1000. [PubMed] [Google Scholar]
  39. Thiagarajan P., Shapiro S. S., Levine E., DeMarco L., Yalcin A. A monoclonal antibody to human platelet glycoprotein IIIa detects a related protein in cultured human endothelial cells. J Clin Invest. 1985 Mar;75(3):896–901. doi: 10.1172/JCI111789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Thorsen L. I., Brosstad F., Gogstad G., Sletten K., Solum N. O. Binding of 125I-labelled fibrin(ogen) fragments to platelets and to immunoprecipitated glycoprotein IIb-IIIa complex. Thromb Res. 1986 Jun 1;42(5):645–659. doi: 10.1016/0049-3848(86)90343-9. [DOI] [PubMed] [Google Scholar]
  41. Tobelem G. Mécanisme de l'agrégation plaquettaire et mode d'action des antiagrégants plaquettaires. Rev Prat. 1989 Nov 1;39(25):2219–2222. [PubMed] [Google Scholar]
  42. Weiss H. J., Hawiger J., Ruggeri Z. M., Turitto V. T., Thiagarajan P., Hoffmann T. Fibrinogen-independent platelet adhesion and thrombus formation on subendothelium mediated by glycoprotein IIb-IIIa complex at high shear rate. J Clin Invest. 1989 Jan;83(1):288–297. doi: 10.1172/JCI113871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Yasuda T., Gold H. K., Leinbach R. C., Yaoita H., Fallon J. T., Guerrero L., Napier M. A., Bunting S., Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation. 1991 Mar;83(3):1038–1047. doi: 10.1161/01.cir.83.3.1038. [DOI] [PubMed] [Google Scholar]
  44. de Groot P. G., Sixma J. J. Platelet adhesion. Br J Haematol. 1990 Jul;75(3):308–312. doi: 10.1111/j.1365-2141.1990.tb04341.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES